Carfilzomib/Pomalidomide and Dexamethasone for Relapsed/Refractory MM


Carfilzomib/Pomalidomide and Dexamethasone for Relapsed/Refractory MM
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Rafael Fonseca, MD (2/14/14)
Shah JJ et al. Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Proc ASH 2013;Abstract 690.

Dr Fonseca is Getz Family Professor of Cancer and Chair of the Department of Internal Medicine at the Mayo Clinic Arizona in Scottsdale, Arizona.